Guideline-directed Management and Therapy (GDMT) for the Prevention of Postpartum Cardiac Dysfunction in Preeclamptic African American Women

Launched by UNIVERSITY OF CHICAGO · Sep 6, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how a specific treatment approach called Guideline-directed Management and Therapy (GDMT) can help prevent heart problems in African American women who have experienced preeclampsia after childbirth. Preeclampsia is a condition that can occur during pregnancy, leading to high blood pressure and other complications. The study aims to see if this treatment can improve a measurement known as Global Longitudinal Strain (GLS), which helps assess heart function.

To participate in the trial, women need to be between 18 and 45 years old, identify as African American, and have been diagnosed with preeclampsia during their pregnancy. They also need to have high blood pressure during a follow-up appointment six months after giving birth. Participants will be recruited from the University of Chicago Medical Center and will use a special tablet device to help monitor their health during the study. This is an important opportunity for eligible women to receive targeted care and contribute to research that may improve health outcomes for others in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Adults between 18 and 45 years of age
• • 2. African American
• • 3. \>120/80 BP at the time of their 6-month visit in the PARENT study
• • 4. Diagnosed with preeclampsia
• • 5. Initially presented to University of Chicago Medical Center (UCMC) for a Singleton Gestation Delivery
• • 6. Completed the 6 month visit in the PARENT study
• Exclusion Criteria:
• • 1. Those who cannot provide consent
• • 2. patients with preexisting cardiomyopathy, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestations,
• • 3. Unable to operate the RPM tablet device